Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study)

Scandinavian Journal of Infectious Diseases

Volumn 46, Issue 1, 2014, Pages 34-45

  Fabbiani, Massimiliano ^a   Mondi, Annalisa ^a   Colafigli, Manuela ^a   D'ettorre, Gabriella ^b   Paoletti, Francesca ^b   D'avino, Alessandro ^a   Ciccarelli, Nicoletta ^a   Sidella, Letizia ^a   Murri, Rita ^a   Fortuna, Serena ^a   Vullo, Vincenzo ^b   Cauda, Roberto ^a   De Luca, Andrea ^a,c   Di Giambenedetto, Simona ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Antiretroviral therapy; HIV; Raltegravir; Toxicity; Treatment simplification

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; CHOLESTEROL; CORTICOSTEROID; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BASAL CELL CARCINOMA; BLOOD SAMPLING; BODY FAT DISTRIBUTION; BONE MASS; CANCER SURGERY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOCHOLESTEROLEMIA; HYPOLIPEMIA; INFECTION CONTROL; KIDNEY TUBULE DISORDER; LABORATORY TEST; MALE; METABOLIC DISORDER; MIDDLE AGED; NEUROLOGIC DISEASE; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHYSICAL EXAMINATION; PILOT STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV INFECTIONS; HUMANS; LIPIDS; MALE; MIDDLE AGED; PILOT PROJECTS; PYRROLIDINONES; QUALITY OF LIFE; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84890903531     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2013.840920     Document Type: Article

References (40)

1. Sweet DE. M etabolic complications of antiretroviral therapy. Top HIV Med 2005;13: 70-4
2. Strategies for Management of Anti-Retroviral Therapy/ INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22: F17-24
3. Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011;76: 1403-9
4. Winston J, Deray G, Hawkins T, Szczech L, Wyatt C, Young B. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis 2008;47: 1449-57
5. Guti é rrez F, Masi á M. The role of HIV and antiretroviral therapy in bone disease. AIDS Rev 2011;13: 109-18
6. Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatmentnaive human immunodefi ciency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011 ; 53: 807-16
7. Steigbigel R T, Cooper D A, Teppler H, Eron J J, Gatell JM, Kumar PN, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drug-resistant HIV infection: Week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010;50: 605-12
8. Fabbiani M, Di Giambenedetto S, Ragazzoni E, D 'E ttorre G, Parruti G, Prosperi M, et al. Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: Potential role for an unexpected drug interaction. Pharmacol Res 2011;63: 249-53
9. Cattaneo D, Gervasoni C, Cozzi V, Baldelli S, Fucile S, Meraviglia P, et al. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients. Pharmacol Res 2012;65: 198-203
10. Fabbiani M, Navarra P, Cauda R, De Luca A, Di Giambenedetto S. Is there a drug - Drug interaction between darunavir/ ritonavir and raltegravir? J Acquir Immune Defi c Syndr 2012;60: E18-20
11. Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir - Ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): Two multicentre, doubleblind, randomised controlled trials. Lancet 2010;375 : 396-407
12. Mart í nez E, Larrousse M, Llibre JM, Guti é rrez F, Saumoy M, Antela A, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study. AIDS 2010;24: 1697-707
13. Vispo E, Barreiro P, Maida I, Mena A, Blanco F, Rodr í guez-Novoa S, et al. Simplifi cation from protease inhibitors to once- or twice-daily raltegravir: The ODIS trial. HIV Clin Trials 2010;11: 197-204
14. Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, et al. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother 2011;66: 2099-106
15. Santos JR, Llibre JM, Ferrer E, Domingo P, Imaz A, Molt ó J, et al. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression. HIV Clin Trials 2009;10: 432-8
16. Division of AIDS (DAIDS). T able for grading the severity of adult and pediatric adverse events. National Institutes of Health;December, 2004. Available at: Http: //www.niaid.nih. gov/LabsAndResources/resources/ DAIDSClinRsrch/ Documents/daidsaegradingtable.pdf (accessed 1 July 2013
17. Fortuna S, Ragazzoni E, Lisi L, Di Giambenedetto S, Fabbiani M, Navarra P. Validation of an UPLC-MS/MS method for quantitative analysis of raltegravir in human plasma samples. Ther Drug Monit 2013;35: 258-63
18. Fortuna S, Fabbiani M, Di Giambenedetto S, Ragazzoni E, Lisi L, Cauda R, et al. Variability of raltegravir plasma levels in the clinical setting. Pharmacology 2013;92: 43-8
19. Murri R, Cingolani A, De Luca A, Di Giambenedetto S, Marasca G, De Matteis G, et al. Asymmetry of the regimen is correlated to self-reported suboptimal adherence: Results from AdUCSC, acohort study on adherence in Italy. J Acquir Immune Defi c Syndr 2010;55: 411-2
20. Bartels C, Wegrzyn M, Wiedl A, Ackermann V, Ehrenreich H. Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive testing. BMC Neurosci 2010;11: 118
21. Grima P, Fabbiani M, Ciccarelli N, Tana M, Farina S, Colafi gli M, et al. Increased ophthalmic artery resistance index is associated with cognitive impairment in HIVinfected patients. J Infect 2012;65: 439-46
22. Fabbiani M, Ciccarelli N, Tana M, Farina S, Baldonero E, Di Cristo V, et al. Cardiovascular risk factors and carotid intima-media thickness are associated to lower cognitive performance in HIV-infected patients. HIV Med 2013;14 : 136-44
23. Arribas JR, Horban A, Gerstoft J, Fä t kenheuer G, Nelson M, Clumeck N, et al. The MONET trial: Darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010;24: 223-30
24. Di Giambenedetto S, Fabbiani M, Colafi gli M, Ciccarelli N, Farina S, Sidella L, et al. Safety and feasibility of treatment simplifi cation to atazanavir/ritonavir lamivudine in HIVinfected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplifi cation, AtLaS pilot study). J Antimicrob Chemother 2013;68: 1364-72
25. Calza L, Manfredi R, Colangeli V, Pocaterra D, Rosseti N, Pavoni M, et al. Efficacy and safety of atazanavir - Ritonavir plus abacavir - Lamivudine or tenofovir - Emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care STDS 2009;23: 691-7
26. Mart í nez E, Arranz J A, Podzamczer D, Loncá M, Sanz J, Barrag á n P, et al. A simplifi cation trial switching from nucleoside reverse transcriptase inhibitors to once-daily fi xeddose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defi c Syndr 2009;51: 290-7
27. Sax PE, Tierney C, Collier A C, Daar ES, Mollan K, Budhathoki C, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: Fi nal results. J Infect Dis 2011;204 : 1191-201
28. Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ ritonavir for initial HIV treatment. AIDS 2009;23: 1547-56
29. Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/ lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defi c Syndr 2010;55: 49-57
30. P é rez-Molina J A, Serrano O, Milinkovic A, Domingo P, Curr á n A, Knobel H, et al. Comparison of antiviral activity of regimens containing nucleos(t)ide (NUC) pairs in HIVinfected patients initiating rescue therapy (The NUCREST Study). HIV Clin Trials 2010;11: 294-302
31. Sax P E, Tierney C, Collier AC, Fischl M A, Mollan K, Peeples L, et al. Abacavir - Lamivudine versus tenofovir - Emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361: 2230-40
32. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: Renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51: 496-505
33. Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, Moran L, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 2010;24: 1781-4
34. Fabbiani M, Bracciale L, Doino M, Sidella L, Farina S, Di Cristo V, et al. Lipid-lowering effect of tenofovir in HIV-infected patients. J Antimicrob Chemother 2011;66 : 682-3
35. Dahl V, Lee E, Peterson J, Spudich SS, Leppla I, Sinclair E, et al. Raltegravir treatment intensifi cation does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis 2011;204 : 1936-45
36. Yilmaz A, Gissl é n M, Spudich S, Lee E, Jayewardene A, Aweeka F, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009;4: E6877
37. Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defi c Syndr 2010;55: 39-48
38. Curran A, Martinez E, Saumoy M, del Rio L, Crespo M, Larrousse M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRALLIP substudy. AIDS 2012;26: 475-81
39. Haubrich R H, Riddler S A, DiRienzo AG, Komarow L, Powderly WG, Klingman K, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23: 1109-18
40. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002;359: 1841-50